<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article4</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/COLCOT" style="display:block; margin-bottom:10px;">COLCOT Original</a></li>
<h2><strong>COLCOT</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Colchicine in Patients with Recent Myocardial Infarction".The New England Journal of Medicine. 2019. DOI: 10.1056/NEJMoa1912388.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does low-dose colchicine reduce the risk of ischemic cardiovascular events in patients with a recent myocardial infarction?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with a recent myocardial infarction, low-dose colchicine (0.5 mg once daily) significantly reduced the occurrence of ischemic cardiovascular events compared with placebo.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of the knowledge cutoff date, no specific guidelines reflect the results of this trial.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, double-blind, randomized, placebo-controlled trial<br/>
- N=4,745; 2,366 to colchicine, 2,379 to placebo<br/>
- Setting: 167 centers in 12 countries<br/>
- Enrollment: December 2015 - August 2018<br/>
- Follow-up: Median 22.6 months<br/>
- Analysis: Intention-to-treat<br/>
- Primary outcome: Composite of death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to coronary revascularization<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Adult patients within 30 days post-myocardial infarction<br/>
- Completed planned percutaneous revascularization procedures<br/>
- Treated according to national guidelines including intensive statin use<br/>
- Exclusions: Severe heart failure, LVEF &lt; 35%, stroke in previous 3 months, type 2 MI, recent or planned CABG, recent noncutaneous cancer, inflammatory bowel disease, nontransient creatine kinase elevation, hematologic or severe renal/hepatic disease, substance abuse, long-term systemic glucocorticoid therapy, sensitivity to colchicine<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Randomly assigned to receive colchicine (0.5 mg once daily) or placebo<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary outcome occurred in 5.5% (colchicine) compared with 7.1% (placebo) (HR 0.77; 95% CI 0.61-0.96; P=0.02)<br/>
- Stroke (HR 0.26; 95% CI 0.10-0.70)<br/>
- Urgent hospitalization for angina leading to coronary revascularization (HR 0.50; 95% CI 0.31-0.81)<br/>
- Diarrhea reported in 9.7% (colchicine) vs 8.9% (placebo) (P=0.35)<br/>
- Pneumonia as a serious adverse event in 0.9% (colchicine) vs 0.4% (placebo) (P=0.03)<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- The trial's follow-up duration was relatively short (~23 months), limiting assessment of long-term treatment with colchicine.<br/>
- Risks and benefits of prolonged colchicine therapy were not established.<br/>
- Results apply only to patients with recent myocardial infarction and may not generalize to other patient groups.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Supported by the Government of Quebec, the Canadian Institutes of Health Research, philanthropic foundations, with the funds administered by the Montreal Heart Institute.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
Additional information and related trial results can be found at NEJM.org and ClinicalTrials.gov with identifier NCT02551094.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
